Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OH2 Injection in Recurrent Central Nervous System Tumors
NCT05235074Phase 2Completed
- Sponsor
- Wuhan Binhui Biopharmaceutical Co., Ltd.
- Start
- Nov 2021
- Primary completion
- Jul 2026
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of OH2 in central nervous system tumor, glioblastoma (GBM), sponsored by Wuhan Binhui Biopharmaceutical Co., Ltd.. Started Nov 2021; status: completed.
02
Drugs
OH2
03
Conditions
central nervous system tumorglioblastoma (GBM)
Beyond the preview
Go deeper on NCT05235074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05235074.